232 related articles for article (PubMed ID: 21694846)
1. Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.
Wong BS; Manabe N; Camilleri M
Clin Exp Gastroenterol; 2010; 3():49-56. PubMed ID: 21694846
[TBL] [Abstract][Full Text] [Related]
2. Use of prucalopride in adults with chronic idiopathic constipation.
Vijayvargiya P; Camilleri M
Expert Rev Clin Pharmacol; 2019 Jul; 12(7):579-589. PubMed ID: 31096799
[No Abstract] [Full Text] [Related]
3. Patient considerations in the management of chronic constipation: focus on prucalopride.
Shin A
Patient Prefer Adherence; 2016; 10():1373-84. PubMed ID: 27528801
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of prucalopride in adults and children with chronic constipation.
Diederen K; Mugie SM; Benninga MA
Expert Opin Pharmacother; 2015 Feb; 16(3):407-16. PubMed ID: 25539475
[TBL] [Abstract][Full Text] [Related]
5. Prucalopride: the evidence for its use in the treatment of chronic constipation.
Coremans G
Core Evid; 2008 Jun; 3(1):45-54. PubMed ID: 20694083
[TBL] [Abstract][Full Text] [Related]
6. An update on prucalopride in the treatment of chronic constipation.
Omer A; Quigley EMM
Therap Adv Gastroenterol; 2017 Nov; 10(11):877-887. PubMed ID: 29147138
[TBL] [Abstract][Full Text] [Related]
7. Prucalopride.
Frampton JE
Drugs; 2009; 69(17):2463-76. PubMed ID: 19911858
[TBL] [Abstract][Full Text] [Related]
8. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
Tack J; van Outryve M; Beyens G; Kerstens R; Vandeplassche L
Gut; 2009 Mar; 58(3):357-65. PubMed ID: 18987031
[TBL] [Abstract][Full Text] [Related]
9. Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation.
Tameez Ud Din A; Khan AH; Bajwa H; Maqsood MH; Malik MN
Cureus; 2019 Apr; 11(4):e4382. PubMed ID: 31218146
[TBL] [Abstract][Full Text] [Related]
10. Prucalopride for chronic constipation.
Lacy BE; Loew B; Crowell MD
Drugs Today (Barc); 2009 Dec; 45(12):843-53. PubMed ID: 20135019
[TBL] [Abstract][Full Text] [Related]
11. Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae.
Chai W; Chan KY; de Vries R; van den Bogeardt AJ; de Maeyer JH; Schuurkes JA; Villalón CM; Saxena PR; Danser AH; MaassenVanDenBrink A
Life Sci; 2012 Apr; 90(13-14):538-44. PubMed ID: 22326501
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.
Tack J; Camilleri M; Chang L; Chey WD; Galligan JJ; Lacy BE; Müller-Lissner S; Quigley EM; Schuurkes J; De Maeyer JH; Stanghellini V
Aliment Pharmacol Ther; 2012 Apr; 35(7):745-67. PubMed ID: 22356640
[TBL] [Abstract][Full Text] [Related]
13. Prucalopride: safety, efficacy and potential applications.
Quigley EM
Therap Adv Gastroenterol; 2012 Jan; 5(1):23-30. PubMed ID: 22282705
[TBL] [Abstract][Full Text] [Related]
14. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
Quigley EM; Vandeplassche L; Kerstens R; Ausma J
Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical Cardiovascular Studies of Prucalopride, a Highly Selective 5-Hydroxytryptamine 4 Receptor Agonist.
Conlon K; De Maeyer JH; Bruce C; Schuurkes JAJ; Christie L; McRedmond J; Derakhchan K; Wade PR
J Pharmacol Exp Ther; 2018 Feb; 364(2):156-169. PubMed ID: 29180358
[TBL] [Abstract][Full Text] [Related]
17. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
18. [Some practical questions on chronic stipsis treatment with prucalopride].
Bellacosa L; Cogliandro R; Cremon C; De Giorgio R; Barbara G; Stanghellini V
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):85-99. PubMed ID: 24632771
[TBL] [Abstract][Full Text] [Related]
19. A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation.
Tack J; Derakhchan K; Gabriel A; Spalding W; Terreri B; Youssef A; Kreidieh B; Kowey PR; Boules M
Am J Gastroenterol; 2023 Jun; 118(6):955-960. PubMed ID: 36927957
[TBL] [Abstract][Full Text] [Related]
20. Prucalopride: a review of its use in the management of chronic constipation.
Keating GM
Drugs; 2013 Nov; 73(17):1935-50. PubMed ID: 24194435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
